NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
2cureX AB (ST: 2CUREX)
2CUREX Technical Analysis
5
As on 21st Nov 2024 2CUREX STOCK Price closed @ 0.48 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.49 & Strong Sell for SHORT-TERM with Stoploss of 4.23 we also expect STOCK to react on Following IMPORTANT LEVELS. |
2CUREXSTOCK Price
Open | 0.48 | Change | Price | % |
High | 0.48 | 1 Day | -0.01 | -2.04 |
Low | 0.48 | 1 Week | -0.05 | -9.43 |
Close | 0.48 | 1 Month | -0.08 | -14.29 |
Volume | 5702 | 1 Year | -4.66 | -90.66 |
52 Week High 5.20 | 52 Week Low 0.26 |
ST Sweden Most Active Stocks
TANGI | 0.00 | % |
FING-B | 0.08 | 0.00% |
SBB-B | 4.00 | 1.78% |
LUNE | 21.97 | 6.65% |
SNM | 0.88 | 2.33% |
DIABIO | 0.03 | 0.00% |
WYLD | 0.02 | 0.00% |
NIBE-B | 45.75 | 1.87% |
HDW-B | 0.00 | % |
EURA | 0.01 | 0.00% |
ST Sweden Top Gainers Stocks
ST Sweden Top Losers Stocks
2CUREX Daily Charts |
2CUREX Intraday Charts |
Whats New @ Bazaartrend |
2CUREX Free Analysis |
|
2CUREX Important Levels Intraday
RESISTANCE | 0.48 |
RESISTANCE | 0.48 |
RESISTANCE | 0.48 |
RESISTANCE | 0.48 |
RESISTANCE | 0.48 |
RESISTANCE | 0.48 |
RESISTANCE | 0.48 |
RESISTANCE | 0.48 |
2CUREX Forecast November 2024
4th UP Forecast | 3.29 |
3rd UP Forecast | 2.39 |
2nd UP Forecast | 1.83 |
1st UP Forecast | 1.28 |
1st DOWN Forecast | -0.32 |
2nd DOWN Forecast | -0.87 |
3rd DOWN Forecast | -1.43 |
4th DOWN Forecast | -2.33 |
2CUREX Weekly Forecast
4th UP Forecast | 2.79 |
3rd UP Forecast | 2.05 |
2nd UP Forecast | 1.59 |
1st UP Forecast | 1.13 |
1st DOWN Forecast | -0.17 |
2nd DOWN Forecast | -0.63 |
3rd DOWN Forecast | -1.09 |
4th DOWN Forecast | -1.83 |
2CUREX Forecast2024
4th UP Forecast | 9.96 |
3rd UP Forecast | 6.92 |
2nd UP Forecast | 5.04 |
1st UP Forecast | 3.16 |
1st DOWN Forecast | -2.2 |
2nd DOWN Forecast | -4.08 |
3rd DOWN Forecast | -5.96 |
4th DOWN Forecast | -9 |
2cureX AB ( ST Sweden Symbol : 2CUREX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
2CUREX Other Details
Segment | EQ | |
Market Capital | 265881744.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
2CUREX Address
2CUREX Latest News
2CUREX Business Profile
2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat test that allows the physician to identify a medical treatment that is effective for a particular cancer patient. IndiTreat establishes thousands of 3D micro-tumors that are similar to the patient's tumor and identifies the treatment that kills the patient's tumor. The company is also conducting various clinical programs for IndiTreat for colorectal, ovarian, and pancreatic cancers. 2cureX AB has clinical partnerships with Skåne University Hospital in Sweden; and University Medical Center Hamburg-Eppendorf. The company was incorporated in 2006 and is based in Copenhagen, Denmark. Address: Fruebjergvej 3, Copenhagen, Denmark, 2100
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service